A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
71actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-27 | actual | When the study began enrolling |
| Primary completion | 2026-02-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-23 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: PF-08049820
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Treatment Emergent Adverse Events (TEAEs)
measured Baseline up to Day 35 of last dosing period for Parts A and C and up to Day 45 for Part B
Number of Participants With Serious Adverse Events (SAEs)
measured Baseline up to Day 35 of last dosing period for Parts A and C and up to Day 45 for Part B
Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities
measured Baseline up to Day 21 of last dosing period for Parts A and C and up to Day 31 for Part B
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
measured Baseline up to Day 21 of last dosing period for Parts A and C and up to Day 31 for Part B
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings
measured Baseline up to Day 21 of last dosing period for Parts A and C and up to Day 31 for Part B
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed